Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety

The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least tw...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karina E. Zatolochina, Sergey K. Zyryanov, Elena A. Ushkalova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	cd38 antibody isatuximab multiple myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/25784a31084f4d508ceb6bc0d0ac9915
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25784a31084f4d508ceb6bc0d0ac9915
record_format	dspace
spelling	oai:doaj.org-article:25784a31084f4d508ceb6bc0d0ac99152021-11-30T16:55:01ZIsatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety1815-14341815-144210.26442/18151434.2021.2.200926https://doaj.org/article/25784a31084f4d508ceb6bc0d0ac99152021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/73206/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least two lines therapies, including lenalidomide and a proteasome inhibitor. The published data from studies of isatuximab, demonstrating its clinical efficacy and safety in combination with standard treatment regimens for recurrent/refractory MM, are discussed.Karina E. ZatolochinaSergey K. ZyryanovElena A. UshkalovaIP Habib O.N.articlecd38antibodyisatuximabmultiple myelomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 327-331 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	cd38 antibody isatuximab multiple myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cd38 antibody isatuximab multiple myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Karina E. Zatolochina Sergey K. Zyryanov Elena A. Ushkalova Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
description	The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least two lines therapies, including lenalidomide and a proteasome inhibitor. The published data from studies of isatuximab, demonstrating its clinical efficacy and safety in combination with standard treatment regimens for recurrent/refractory MM, are discussed.
format	article
author	Karina E. Zatolochina Sergey K. Zyryanov Elena A. Ushkalova
author_facet	Karina E. Zatolochina Sergey K. Zyryanov Elena A. Ushkalova
author_sort	Karina E. Zatolochina
title	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
title_short	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
title_full	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
title_fullStr	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
title_full_unstemmed	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
title_sort	isatuximab, a novel anti-cd38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/25784a31084f4d508ceb6bc0d0ac9915
work_keys_str_mv	AT karinaezatolochina isatuximabanovelanticd38monoclonalantibodyinthetreatmentofmultiplemyelomaefficacyandsafety AT sergeykzyryanov isatuximabanovelanticd38monoclonalantibodyinthetreatmentofmultiplemyelomaefficacyandsafety AT elenaaushkalova isatuximabanovelanticd38monoclonalantibodyinthetreatmentofmultiplemyelomaefficacyandsafety
_version_	1718406433774501888

Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety

Ejemplares similares